Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis.
Sinigiani G, Sanna GD, Aimo A, Porcari A, Bonacchi G, De Michieli L, Milani P, Vergaro G, Tini G, Baldan M, Martire P, Beghini A, Tomasoni D, Palmiero G, Ossola P, Musca F, Zampieri M, Guidi Colombi G, Serenelli M, Cemin R, Iseppi M, Moretti M, Giacomin E, Negri F, Driussi M, Nuvolone M, Zanoletti M, Bianco M, Chinaglia A, Faro D, Ruotolo I, Longhi S, Monte IP, Lorenzoni G, Gregori D, Imazio M, Canepa M, Ricci F, Merlo M, Perazzolo Marra M, Limongelli G, Musumeci B, Perlini S, Cappelli F, Metra M, Corrado D, Sinagra G, Emdin M, Palladini G, Cipriani A.
Sinigiani G, et al. Among authors: emdin m.
JACC Heart Fail. 2025 Jul 2;13(8):102549. doi: 10.1016/j.jchf.2025.102549. Online ahead of print.
JACC Heart Fail. 2025.
PMID: 40609138
Free article.
No abstract available.